Skip to main content
OpenTrials
Completed

NCT Number: NCT03778502

DOAC in Unusual Site Venous Thrombosis

Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Splanchnic Vein Thrombosis Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebral Vein Thrombosis Cerebrovascular Disorders Embolism and Thrombosis Eye Diseases Intracranial Embolism and Thrombosis Intracranial Thrombosis Nervous System Diseases Ovarian Vein Thrombosis Renal Vein Thrombosis Retinal Diseases Retinal Vein Occlusion Retinal Vein Thrombosis Thromboembolism Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ottawa Hospital Research Institute, Ottawa, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Objective diagnosis of venous thrombosis not involving the upper limbs, lower limbs and pulmonary arteries
  • Treatment with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban)

Exclusion criteria

  • Enrolment in interventional studies evaluating the DOAC for the treatment of unusual site VTE

Treatment and study plan

Direct Oral Anticoagulants

Drug

Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry

Other names: Apixaban, Dabigatran, Edoxaban, Rivaroxaban

Primary outcomes

  1. Rationale for the use of the direct oral anticoagulants

    Time frame: Baseline

    Possible reasons for choosing one of the direct oral anticoagulant (multiple choice question)

Secondary outcomes

  1. Rate of major bleeding events

    Time frame: 12 months

  2. Rate of vascular events

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

University of Malta

Other

Collaborators

  • Università degli Studi dell'Insubria

Registry information

Official study title

International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism

Acronym: DUST

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Dec 19, 2018
Registry last updated
Jul 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.